This research found that inhibiting PKC-ι, in conjunction with PI3K, promoted apoptosis and that PKC-ι can be considered as a therapeutic target in the treatment of ccRCC. The gene discussed is PRKCI; the disease is nonpapillary renal cell carcinoma.